Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News
Top-Ergebnisse: 1,75 g/t Gold über 30,4 Meter + massives Tagebau-Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
65 Leser
Artikel bewerten:
(0)

An Additional $10.5 Million In Federal Research Funding Secured For Lung Cancer

FY 2014 Omnibus Appropriations Bill Brings New Total to Nearly $80 Million Secured Via Department of Defense Lung Cancer Research Program

WASHINGTON, Jan. 18, 2014 /PRNewswire-USNewswire/ -- Today, Lung Cancer Alliance (LCA) proudly announced that an additional $10.5 million for lung cancer research was signed into law by President Barack Obama as part of the FY 2014 Omnibus Appropriations bill. With the approval of this funding, the new total amount of federal research dollars secured to date is nearly $80 million.

In FY 2009, LCA succeeded in establishing this first-ever dedicated Lung Cancer Research Program (LCRP) within the Department of Defense (DOD) Congressionally Directed Medical Research Program (CDMRP). In the first year of the CDMRP's operation, $20 million was allocated by Congress to fund early detection research targeting at risk military. Since then, Lung Cancer Alliance has succeeded in earmarking additional funding including $15 million in FY 2010, $12.8 million in the FY 2011, $10 million in FY 2012, and $10.5 million in FY 2013. Today's announcement of an additional $10.5 million brings the program total to $78.8 million.

"Increasing federal funding for lung cancer research has always been one of our core priorities," said Laurie Fenton Ambrose, President and CEO of Lung Cancer Alliance. "We remain grateful to congressional leaders for their continued backing of this important research funding stream."

Lung Cancer Alliance Chairman of the Board, Admiral T. Joseph Lopez, USN (Ret.) reinforced his strong backing of for CDMRP funding. "We know that our military are at higher risk of being diagnosed and dying of lung cancer than the civilian population," said Admiral Lopez. "We owe these men and women the benefits of research funding."

Admiral Lopez played a key role in securing the original congressional support for the lung cancer program.

Lung cancer is the leading cause of cancer death among men and women and every ethnic group and takes more lives each year than breast, prostate, colon and pancreatic cancers combined.

About Lung Cancer Alliance:
Lung Cancer Alliance (LCA) is committed to saving lives and accelerating research by empowering people living with or at risk for lung cancer. LCA provides live, professional support, referral and information services to patients, their loved ones and those at risk for lung cancer; conducts national awareness campaigns including the award winning No One Deserves to Die Campaign attacking the stigma of the disease and the Moments Campaign spreading word about the risk and screening with a risk navigator tool for consumers; and advocates for multiple millions in public health dollars for lung cancer research. For more information please visit www.lungcanceralliance.org. Follow Lung Cancer Alliance on Facebook: www.facebook.com/lungcanceralliance and on Twitter @LCAorg.

About Lung Cancer:
Lung cancer is the leading killer in the United States, taking more lives than breast, prostate, colon and pancreatic cancers combined. Each year, an estimated 160,000 lives are lost to lung cancer. Only 15 percent of people diagnosed with lung cancer will survive it. This is primarily because today the vast majority of lung cancers are diagnosed at a late stage. With the US Preventive Services Task Force's recent recommendation that high risk individuals be screened for lung cancer, we anticipate tens of thousands of lives will be saved through early detection.

Media Contact:
Kay Cofrancesco
202-742-1422
kay@lungcanceralliance.org

SOURCE Lung Cancer Alliance

© 2014 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.